Q-omics provides the consensus-scored MIR191 profile across patient tissues and cancer cell-line models. MIR191 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR191 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, MIR191 RNA expression shows 5,195 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, LIHC, and LSCC as cancer lineages where MIR191 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR191 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR191 survival associations across molecular data types. MIR191 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR191 RNA expression–survival associations across cancer types. High MIR191 expression shows unfavorable associations in BRCA, UVM, THCA, UCS and TGCT, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR191 RNA expression.
This table summarizes MIR191 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR191. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR191 shows higher tumor expression in LIHC. The LIHC box plot shows higher MIR191 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .043).
This table shows molecular features associated with MIR191 in patient tissues and cancer cell lines. In patient samples, MIR191 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
